CA2556568A1 - Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang - Google Patents

Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang Download PDF

Info

Publication number
CA2556568A1
CA2556568A1 CA002556568A CA2556568A CA2556568A1 CA 2556568 A1 CA2556568 A1 CA 2556568A1 CA 002556568 A CA002556568 A CA 002556568A CA 2556568 A CA2556568 A CA 2556568A CA 2556568 A1 CA2556568 A1 CA 2556568A1
Authority
CA
Canada
Prior art keywords
optionally
group
branched
linear
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002556568A
Other languages
English (en)
Inventor
Rosa Cuberes Altisen
Bonifacio Guitierrez Silva
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios Del Dr. Esteve S.A.
Rosa Cuberes Altisen
Bonifacio Guitierrez Silva
Jordi Frigola-Constansa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04021974A external-priority patent/EP1637522A1/fr
Application filed by Laboratorios Del Dr. Esteve S.A., Rosa Cuberes Altisen, Bonifacio Guitierrez Silva, Jordi Frigola-Constansa filed Critical Laboratorios Del Dr. Esteve S.A.
Publication of CA2556568A1 publication Critical patent/CA2556568A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
CA002556568A 2004-02-17 2005-02-14 Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang Abandoned CA2556568A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ES200400378 2004-02-17
ES200400378 2004-02-17
US80453404A 2004-03-19 2004-03-19
US10/804,534 2004-03-19
EP04021974A EP1637522A1 (fr) 2004-09-16 2004-09-16 Composés de pyrazolines substituées pour réduire des triglycerides dans le sang
EP04021974.3 2004-09-16
PCT/EP2005/001465 WO2005077909A1 (fr) 2004-02-17 2005-02-14 Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang

Publications (1)

Publication Number Publication Date
CA2556568A1 true CA2556568A1 (fr) 2005-08-25

Family

ID=34864786

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002556568A Abandoned CA2556568A1 (fr) 2004-02-17 2005-02-14 Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang

Country Status (10)

Country Link
EP (1) EP1718619A1 (fr)
JP (1) JP2007522252A (fr)
KR (1) KR20060135815A (fr)
AU (1) AU2005212817A1 (fr)
BR (1) BRPI0507790A (fr)
CA (1) CA2556568A1 (fr)
IL (1) IL177454A0 (fr)
NO (1) NO20064186L (fr)
RU (1) RU2006133260A (fr)
WO (1) WO2005077909A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510647A (ja) 2003-10-30 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体調節剤としてのアラルキルアミン類
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1746090A1 (fr) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
EP1749526A1 (fr) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Utilisation des derivés de la pyrazoline pour le traitement des troubles alimentaires, comme l'obesité ou le syndrome métabolique chez les patients diabetiques
EP1743637A1 (fr) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Utilisation des derivés du pyrazole seuls ou en combinaison pour le traitement du syndrome métabolique
EP1749527A1 (fr) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Utilisation des derivés du pyrazole pour le traitement du syndrome métabolique
WO2007009707A2 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Utilisation de composes a base de pyrazoline substitues pour le traitement de maladies liees a la coagulation
EP1743639A1 (fr) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Utilisation des derivés de la pyrazoline pour le traitement des troubles liées à la coagulation
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
WO2007009701A2 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Utilisation de composes pyrazoliniques substitues pour traiter des facteurs de risque cardiovasculaires imputables a des troubles du metabolisme ou de l'alimentation
EP1743889A1 (fr) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
WO2007009683A2 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A. Formulations pharmaceutiques comprenant des composes de pyrazoline substitues
WO2007009706A2 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Composes de pyrazoline substitues, leur preparation et utilisation comme medicaments
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
EP1745781A1 (fr) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combinaison d'antagoniste du récepteur cannabinoide du type pyrazoline et de statin
WO2007009700A2 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique
WO2007009698A1 (fr) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Association d'une statine et d'un antagoniste pyrazolinique des cannabinoides
EP1944296A1 (fr) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Phase amorphe d'un pyrazoline substitué, sa préparation et utilisation dans le cadre de médicaments
EP1944295A1 (fr) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Mélanges non racémiques de (R)-N-pipéridinyl-5-(4-chlorophényl)1-1(2,4-dichlorophényl)-4,5-dihydro-1H-pyrazole-3-carboxamide et (S)-N-pipéridinyl-5-(4-chlorophényl)-1-(2,4-dichlorophényl)-4,5-dihydro-1H-pyrazole-3-carboxamide
EP1946779A1 (fr) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Combination de pyrazoline substitués et de médicaments contre la dyslipidémie
EP1950203A1 (fr) * 2007-01-24 2008-07-30 Laboratorios del Dr. Esteve S.A. Composés de pyrazoline substitués avec ACAT, leur composition et utilisation en tant que médicaments
EP1947088A1 (fr) * 2007-01-17 2008-07-23 Laboratorios del Dr. Esteve S.A. Composés de pyrazoline substitués présentant une activité inhibitrice de l'ACAT, leur composition et utilisation en tant que médicaments
WO2008087029A1 (fr) * 2007-01-17 2008-07-24 Laboratorios Del Dr. Esteve, S.A. Composés de pyrazoline substituée possédant une activité d'inhibition de l'acat
EP2114892A1 (fr) * 2007-01-17 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Composés de pyrazoline substituée présentant une activité inhibitrice de l'acat, leur préparation et utilisation comme médicaments
KR101395658B1 (ko) 2012-09-20 2014-05-16 서울대학교산학협력단 4-(5-(2-메톡시페닐)-3-(ｐ-톨릴)-4,5-디하이드로-1Ｈ-피라졸-1-일)-4-옥소부탄산을 포함하는 골대사성 질환의 예방 및 치료용 조성물
KR101466377B1 (ko) * 2012-10-22 2014-12-01 건국대학교 산학협력단 디메톡시페닐디히드로피라졸릴나프탈레놀 유도체 및 그 제법 및 항암제로서의 용도
AU2013344605A1 (en) * 2012-11-16 2015-07-02 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
EP2920165B1 (fr) * 2012-11-16 2016-09-28 Bristol-Myers Squibb Company Modulateurs dihydropyrazoles de gpr40

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053661B (it) * 1966-09-27 1981-10-10 Farmacosmici S P A Ammidi dell acido 3 5 metil 5 3 pirazol carbossilico
AU1154488A (en) * 1987-01-05 1988-09-26 E.I. Du Pont De Nemours And Company 1-sub-phenyl-3-sub-phenylamino(thio) carbonyl-pyrazolines as insecticides
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.

Also Published As

Publication number Publication date
BRPI0507790A (pt) 2007-07-17
AU2005212817A1 (en) 2005-08-25
KR20060135815A (ko) 2006-12-29
WO2005077909A1 (fr) 2005-08-25
IL177454A0 (en) 2006-12-10
EP1718619A1 (fr) 2006-11-08
NO20064186L (no) 2006-11-14
JP2007522252A (ja) 2007-08-09
RU2006133260A (ru) 2008-04-10

Similar Documents

Publication Publication Date Title
CA2556568A1 (fr) Composes de pyrazoline substitues permettant de reduire le taux de triglycerides dans le sang
US7994200B2 (en) Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments
EP1849775A1 (fr) Composés de pyrazoline substituées par les cycloalkanes, leur préparation et leur utilisation comme médicaments.
EP1637522A1 (fr) Composés de pyrazolines substituées pour réduire des triglycerides dans le sang
US7998996B2 (en) Substituted pyrazoline compounds for reducing triglycerides in blood
WO2007009704A2 (fr) Utilisation de composes de pyrazoline substitues pour le traitement de troubles lies aux aliments, notamment l'obesite ou le syndrome metabolique chez des malades souffrant du diabete
ES2337005B1 (es) Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos.
WO2007009706A2 (fr) Composes de pyrazoline substitues, leur preparation et utilisation comme medicaments
EP1749526A1 (fr) Utilisation des derivés de la pyrazoline pour le traitement des troubles alimentaires, comme l'obesité ou le syndrome métabolique chez les patients diabetiques
EP1746090A1 (fr) Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
WO2007009699A2 (fr) Utilisation de composes pyrazoliniques substitues et de leurs derives contre des affections associees au systeme des cannabinoides
EP1743638A1 (fr) Formulations pharmaceutiques des derivés de la pyrazoline
EP1743642A1 (fr) Utilisation de composés à base de pyrazoline pour le traitement des maladies associées avec le système cannabinoïde
ES2325569B1 (es) Compuestos de pirazolina cicloalcanosustituidos, su preparacion y su uso como medicamentos.
WO2007009683A2 (fr) Formulations pharmaceutiques comprenant des composes de pyrazoline substitues
ES2327204B1 (es) Compuestos de pirazolina octahidropentalensustituidos, su preparacion y su uso como medicamentos.
ES2327379B1 (es) Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
WO2007009702A2 (fr) Composes de pyrazoline substitues, leur preparation et leur utilisation comme medicaments
EP1849784A1 (fr) Dérivés de la pyrazoline Indoline-substituée, leur préparation and utilisation comme médicaments
EP1849776A1 (fr) Dérivés de la pyrazoline azépane- ou azocane-substituées, leur préparation et utilisation comme médicaments
EP1849783A1 (fr) Composés de pyrazoline substituées par les octahydrocyclopentalenes, leur préparation et leur utilisation comme médicaments.
EP1743889A1 (fr) Composés de pyrazolines substituées ayant une stereochimie predeterminèe pour réduire des triglycerides dans le sang
MXPA06009335A (en) Substituted pyrazoline compounds for reducing triglycerides in blood
WO2007009707A2 (fr) Utilisation de composes a base de pyrazoline substitues pour le traitement de maladies liees a la coagulation
EP1749527A1 (fr) Utilisation des derivés du pyrazole pour le traitement du syndrome métabolique

Legal Events

Date Code Title Description
FZDE Discontinued